Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Cloudbreak Pharma / Equity Capital Markets

<ul>
<li>Cloudbreak Pharma, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.</li>
<li>In this note, we examine the company's core products, namely CBT-001 and CBT-009, for pterygium and juvenile myopia respectively.</li>
<li>We are seeing a lack of convincing sustainable innovation from the company. Pre-IPO investors and management are mediocre.</li>
</ul>


Cloudbreak Pharma, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.
In this note, we examine the company's core products, namely CBT-001 and CBT-009, for pterygium and juvenile myopia respectively.
We are seeing a lack of convincing sustainable innovation from the company. Pre-IPO investors and management are mediocre.


Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cloudbreak Pharma (CBP HK)

Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation

Cloudbreak is a China based clinical stage biotech with a focus on opthalmology drugs. The company is seeking a HK listing and we examine its core...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)